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Abstract 
Background: Lateral ventricular enlargement is one of the most consistent findings in 
patients with schizophrenia; however whether progressive ventricular dilation occurs 
during the course of the illness has been controversial. To clarify this we conducted a 
meta-analysis of longitudinal studies measuring the lateral ventricles in patients with 
schizophrenia and a control group. 
Methods: The MEDLINE database was searched from 1980-2009 for longitudinal MRI 
studies of patients with schizophrenia. We identified 13 studies that measured the 
lateral ventricles in both patients and controls and these were included in a random 
effects meta-analysis. The effect of various clinical variables was investigated in a 
meta-regression analysis. 
Results:  Patients showed evidence of progressive ventricular enlargement after 
illness onset greater than that seen in controls (Effect size=0.45, 95%CI 0.19-0.71, 
p=0.0006). A sub-analysis of chronic patients with schizophrenia with a mean 
duration of illness of 7.6 years at baseline scan also showed progressive ventricular 
enlargement (p=0.002). The results were robust to inclusion criteria, and no 
significant effect of age of onset, duration of illness, or age at baseline scan, was 
found in the meta-regression analysis.  
Conclusions: The meta-analysis shows progressive changes in ventricular volume a 
number of years after illness onset and challenges an exclusively 
neurodevelopmental model of schizophrenia. 
 
Keywords: MRI, schizophrenia, meta-analysis, longitudinal, progressive, ventricle 
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INTRODUCTION 
The presence of structural brain abnormalities in schizophrenia is well established 
(Vita, et al. 2006; Wright, et al. 2000); however the concept of progressive change, 
which may indicate neurodegeneration, is controversial (DeLisi 2008; Weinberger 
and McClure 2002). A number of MRI studies have reported changes in brain 
structure over time in patients with schizophrenia, however the findings appear 
inconsistent and the regions studied frequently differ (DeLisi and Hoff 2005; Kasai, et 
al. 2003). To clarify these findings, we carried out a meta-analysis of lateral 
ventricular volume change in longitudinal MRI studies of patients with schizophrenia 
and control subjects. Although there have been a number of meta-analyses of cross-
sectional MRI studies in schizophrenia (Steen, et al. 2006; Vita, et al. 2006; Wright, et 
al. 2000), to our knowledge this is the first meta-analysis of longitudinal studies. We 
selected the lateral ventricles because cross-sectional meta-analyses have 
repeatedly reported large effect sizes for ventricular dilation (Vita, et al. 2006; 
Wright, et al. 2000), and this region has also been consistently measured in 
longitudinal studies. We hypothesised that patients with schizophrenia would show 
progressive dilation of the lateral ventricles over time compared to controls. In terms 
of moderating variables we predicted that studies with a longer interscan interval 
would show greater volume increases. 
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METHODS AND MATERIALS 
Study selection 
Our strategy in the meta-analysis was to use broad inclusion criteria, and to examine 
the effect of more selective criteria in the sensitivity analysis. Thus the initial 
inclusion criteria for the meta-analysis were peer-reviewed studies which measured 
the lateral ventricles or entire ventricular system in the brain at a minimum of two 
time points using Magnetic Resonance Imaging (MRI) in a group of patients with 
schizophrenia and a control group. We also included studies which combined 
patients with schizophrenia with other psychotic disorders (schizoaffective disorder, 
schizophreniform disorder, and psychosis not otherwise specified). We excluded 
case studies, reviews, publications which had not used standard diagnostic criteria, 
and duplicate publications using the same sample of subjects. Studies using 
Computed Tomography (CT) were excluded to reduce study heterogeneity and 
because of the small number of CT longitudinal studies which included both patients 
and controls. The MEDLINE database was searched up to July 2009 using a 
combination of relevant Medical Subject Headings (MeSH); detailed search terms are 
available from the authors on request. Thirteen publications fulfilled the inclusion 
criteria (see figure 1).  
 
Obtaining change and SD of change measures 
To calculate the effect size for ventricular enlargement we required the change in 
volume from a baseline MRI scan to a follow-up MRI scan and standard deviation of 
change in the patient and control group. For studies where this was not available we 
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contacted the authors directly for these data. Where authors were unable to provide 
us with the data, and the results were presented graphically we measured these to 
obtain means and standard deviations (3 studies), (Degreef, et al. 1991; Nakamura, 
et al. 2007; Rapoport, et al. 1997). Graphs were measured digitally using the GNU 
imaging manipulation program (v2.6.1) measure tool (Mattis and Kimball 2008). 
Studies varied in how they reported the changes in volume. Nine studies reported 
volume change over the entire interscan interval and 4 studies reported mean 
annual volume change. Five studies reported volumetric change in millilitres (ml), 2 
studies reported a percentage change in volume, and for 6 studies we had access to 
both ml and percentage change measures. Studies reporting changes in ml implicitly 
assume a linear growth of ventricular volume over time while studies reporting 
changes in terms of a percentage of the baseline measurement assume an 
exponential growth over time. In the main meta-analysis we included all 13 studies 
and calculated the effect size from volume changes in ml if this measure was 
available; if this measure was not available percentage change was used. To 
determine the validity of combining ml measurement with percentage change, we 
calculated the correlation coefficient between these measures for 6 studies where 
both measurements were given. The correlation was high both in the patient 
(R=0.97, p<0.01) and control group (R=0.96, p<0.01) suggesting the measures are 
comparable. However in addition to the main meta-analysis we also performed 
supplementary meta-analyses separating these two measures (see below). 
  
Three studies reported change in ventricular volume for the left and right ventricle 
separately rather than total lateral ventricular change (DeLisi, et al. 1997; Mathalon, 
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et al. 2001; Whitworth, et al. 2005). To calculate the total ventricular change, the 
sum of the left and right volume change was taken. The standard deviation for total 
volume change was calculated from: 
LRRLRLT ρσσσσσ 222 ++=  
where σT , σL and σR is the standard deviation change in volume for the total, left and 
right ventricle respectively and ρLR is the correlation coefficient between the left and 
right ventricle volume.  For an estimate of ρLR we used the result of an independent 
study (Rao, et al. 2006) which reported a correlation coefficient of 0.78 between the 
left and right lateral ventricle. This technique has also been used in a recent meta-
analysis (Koolschijn, et al. 2009). 
 
Two studies presented measures from subgroups of patients rather than a combined 
patient group. For these studies we entered the subgroups into the meta-analysis as 
if they were separate studies and in each case the number of subjects in the control 
group was the sample size of the control group divided by the number of patient 
subgroups. This technique has also been used in a previous meta-analysis (Kempton, 
et al. 2008). One study reported lateral ventricle volumes using both coronal and 
axial oriented MRI scans (DeLisi, et al. 1997). In this case we selected the coronal MRI 
scans as the majority of studies included in the meta-analysis used this orientation.  
 
Combining study estimates 
Outcome measures were recorded from each study and were re-checked on a 
second occasion by the same investigator (MJK) to ensure accuracy. Hedges g was 
used as the effect size for each study, which is Cohen’s effect size d with a correction 
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for bias from small sample sizes (Hedges and Olkin 1985). The definition of hedges g 
is, 
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where xp and xc is the change in volume in the patient group and control group 
respectively, σpc is the pooled standard deviation of the change measures in the 
patient and control group, and np and nc are the numbers of subjects in the patient 
and control group respectively. 
 
The standardised effect sizes were subsequently pooled using a random-effects 
inverse weighted variance model, (DerSimonian and Laird 1986). The true effect is 
assumed to have a normal distribution in the population of studies, and the aim of 
the random effects model meta-analysis is to estimate the mean of this distribution. 
Random effects models generally produce wider confidence intervals and are more 
conservative than fixed effects models. The meta-analyses were performed in STATA 
9.2 (StatCorp 2006) using the METAN command (Bradburn, et al. 1998). 
 
Assessing between-study heterogeneity 
The heterogeneity of effect sizes was assessed formally by applying Cochran’s q test 
for homogeneity (Sutton 2000) and informally by assessing a sample size 
independent descriptive measure of inconsistency I
2  
(Higgins, et al. 2003). The I
2 
measure describes the percentage of total variation across studies that is due to 
heterogeneity of the effect sizes. I
2
 ranges between 0 (no inconsistency) and 100% 
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with values of 25%, 50% and 75% suggested as low, moderate and high 
heterogeneity.  
 
 
Publication bias 
Publication bias may be assessed by visually inspecting a funnel plot, which displays a 
measure of study precision against study effect size. We used Egger’s regression test 
which is a formal method of assessing publication bias (Egger, et al. 1997) as 
implemented with the STATA function METABIAS (Steichen 1998). 
 
Subgroup meta-analyses 
A meta-analysis of outcome measures of first-episode patients who were scanned at 
baseline (4 studies) was computed and compared to a meta-analysis of patients with 
chronic schizophrenia at baseline (8 studies). One study reported outcome measures 
separately for first episode and chronic patients; the results from these subgroups 
were included in each meta-analysis as appropriate. To compare the effect sizes 
from the two patient groups a Z-test was used.  As studies reported results in terms 
of ml and percentage change, we also performed two separate meta-analyses for 
these measures.  
 
Exploratory meta-regression of clinical variables  
The effects of clinical variables were assessed in a random effects meta-regression 
model by using the METAREG (Sharp 1998) command in STATA 9.2. The default 
option using residual maximum likelihood (REML) was selected. As the meta-
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regression was exploratory and 7 variables were investigated, results were 
considered significant if they passed a Bonferroni corrected p-value <0.007. 
 
 
Sensitivity analysis  
To test how robust the results were to variations in the meta-analysis methodology, 
we examined the effect of the following on the meta-analysis estimate, a) excluding 
3 studies which combined schizophrenia with other psychotic disorders, b) excluding 
2 studies which had measured the entire ventricular system rather than the lateral 
ventricles only, c) excluding 3 studies where we had obtained an effect size from 
measuring graphical data, d) changing the correlation coefficient between the left 
and right ventricle volume to 0.1 and 1, and e) repeating the meta-analysis 13 times 
each time excluding one study. 
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RESULTS 
Main meta-analysis 
The meta-analysis comprised 13 studies with a total of 473 patients and 348 control 
subjects (see table 1 and 2). Patients with schizophrenia and psychotic disorders 
showed increased rates of lateral ventricle dilation over time compared to controls 
(13 studies, Effect size g=0.449, 95%CI 0.192-0.707, p=0.0006), see figure 2. There 
was significant moderate to high between-study heterogeneity (I
2
=63%, Q=37.3, 
p<0.001) and no evidence of publication bias (p=0.27).  
 
Subgroup meta-analyses 
First episode patients compared to chronic patients 
When the meta-analysis was restricted to studies of first episode patients (as 
assessed at baseline) there was a similar effect size to the main meta-analysis 
although this was not significant (5 studies, mean age of onset=25.5, mean interscan 
interval=2.1 years, Effect size g=0.491, 95%CI -0.113 to 1.095, p=0.11). In a meta-
analysis of studies of chronic patients, significant progression was found (9 studies, 
mean duration of illness at baseline scan=7.6 years, mean age of onset=19.6, mean 
interscan interval=3.7 years, Effect size g=0.407, 95%CI 0.134 to 0.679, p=0.003). 
There was no significant difference in effect size between studies which scanned first 
episode patients at baseline versus patients with chronic illness (Difference in effect 
size g=0.08, 95%CI -0.542 to 0.711, p=0.79). 
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Studies reporting a fixed volume change 
In a sub-analysis we only included studies which reported changes in absolute 
volume (ml) over time (11 studies). Patients with schizophrenia and psychotic 
disorders showed increased rates of lateral ventricle dilation in terms of absolute 
volume change over time compared to controls (Effect size g=0.320, 95%CI 0.101 to 
0.540, p=0.004). There was significant moderate between-study heterogeneity 
(I
2
=43%, Q=21.1, p=0.049) and no evidence of publication bias (p=0.60). The ratio of 
mean volume change in patients per year to the mean volume change in controls per 
year was 2.9.  
 
Studies reporting a percentage volume change 
When the effect size was calculated from percentage change in ventricular volume 
over time (8 studies), patients with schizophrenia and psychotic disorders showed 
increased rates of lateral ventricle dilation compared to controls (Effect size g=0.646, 
95%CI 0.220 to 1.071, p=0.003). There was significant moderate to high between-
study heterogeneity (I
2
=67%, Q=21.1, p=0.004) and no evidence of publication bias 
(p=0.64). The ratio of the mean percentage volume change in patients per year to 
the mean percentage volume change in controls per year was 4.3. 
 
Exploratory meta-regression of clinical variables 
There was no significant association (Bonferroni corrected p<0.007) between the 
following variables and study effect size: mean patient interscan interval (13 studies, 
p=0.49), mean patient age at baseline scan (13 studies, p=0.79), percentage of 
female patients (11 studies, p=0.27) mean duration of illness at baseline scan (13 
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studies, p=0.61) and mean age of onset (13 studies, p=0.31). In addition there was no 
association between the percentage of patients using typical (5 studies, p=0.50) or 
atypical neuroleptic medication (5 studies p=0.31) and study effect size. A meta-
regression examining the effects of medication dosage was not possible as only 3 
studies reported dosage in terms of chlorpromazine equivalents. However 6 of the 
13 studies examined correlations between ventricular volume change and 
medication dosage and/or compliance. Four of these reported no significant 
correlation and 2 studies reported correlations showing that medication compliance 
was associated with a slowing of ventricular enlargement (DeLisi, et al. 1997; Nair, et 
al. 1997). In terms of other within-study correlations, 5 studies reported that 
progressive ventricular enlargement was associated with a significantly poorer 
outcome or higher symptom score (Ho, et al. 2003; Lieberman, et al. 2005; 
Nakamura, et al. 2007; Rapoport, et al. 1997; van Haren, et al. 2008). We did not 
identify any other consistent correlations from individual studies. 
 
Sensitivity analysis 
The result of the main meta-analysis remained significant (Effect size g=0.29 to 0.52, 
all p<0.003) when we a) excluded studies which had recruited patients with 
psychotic disorders other than schizophrenia, b) excluded studies which measured 
the entire ventricular system rather than the lateral ventricles only c) excluded 
studies where effect sizes were calculated from graphical data, d) entered a 
correlation coefficient between the left and right ventricle volume as 0.1 and 1, or e) 
repeated the meta-analysis 13 times each time excluding one study. 
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DISCUSSION 
In this meta-analysis we have shown that lateral ventricular volume continues to 
increase in patients with schizophrenia after illness onset. The ratio of patient to 
control changes in volume, suggest that the increase observed in patients is 
approximately 3 to 4 times that observed in normal aging. In a sub-analysis, 
progression of ventricular volume was also found in chronic patients who had been 
ill for an average of 7.6 years. We did not find significant ventricular progression in 
patients with first episode schizophrenia, although it is likely that this analysis was 
underpowered as only 5 studies were available. In addition the effect size for first 
episode patients (g=0.49) was comparable to the main analysis (g=0.45) suggesting 
that progression may also occur early in the illness. In the meta-regression analysis 
we did not find any relation between progression in lateral ventricular volume and 
interscan interval or other clinical variables.  
 
There was a wide variation of ventricular change observed both within and between 
studies. Although robust, an effect size of g=0.45 indicates there is overlap in rates of 
progression between patients with schizophrenia and controls, and that a minority 
of patients show less progression that the control group mean. Large neuroimaging 
studies may reveal if there are distinct subgroups of patients, some of whom show 
progression, and others who show no change in ventricular volume. Although 
preliminary, our examination of within study correlations suggest that a progressive 
course may be associated with poorer outcome.  
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Evidence for schizophrenia as a neurodevelopmental disorder is consistent with a 
number of findings in patients with schizophrenia such as minor physical anomalies 
(Weinberg, et al. 2007), neurological soft signs (Chan, et al. 2009), reduced brain 
asymmetry (Sommer, et al. 2001) and an increased rates of obstetric complications 
(Geddes, et al. 1999). Static volumetric deficits in brain structure have been cited as 
supporting the neurodevelopmental hypothesis of schizophrenia so progressive 
changes are problematic to an exclusively neurodevelopmental theory. However in 
terms of our meta-analysis supporting a neurodegenerative process, it is important 
to stress that neuropathological studies argue against conventional 
neurodegeneration (Harrison and Weinberger 2005) and that MRI cannot measure 
neurodegeneration directly. Nonetheless these findings deserve further investigation 
by post-mortem studies and novel positron emission tomography (PET) tracers 
(Zhou, et al. 2009) which may be able to elucidate the mechanism of progressive 
volume change.  
 
Interestingly, changes in ventricular volume may be more strongly associated with 
environmental than genetic factors. Cross-sectional studies show a strong influence 
of the environment on ventricular volume in both healthy controls (Baare, et al. 
2001) and patients with schizophrenia (McNeil, et al. 2000). In addition one 
longitudinal study of twin pairs discordant for schizophrenia has suggested that 
progressive changes in ventricular volume are associated with nonshared 
environmental effects (Brans, et al. 2008).    
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Are progressive changes an effect of medication? 
Although studies in first episode patients suggest that ventricular enlargement per se 
is not a direct result of medication (Steen, et al. 2006; Vita, et al. 2006), it is difficult 
to separate the effect of medication and chronic illness on progressive changes in 
ventricular volume. Nearly all patients with schizophrenia over a period of one or 
more years would be medicated, and testing the effects of neuroleptics on brain 
structure in healthy controls over a long period is clearly not ethical.  A study in 
macaque monkeys found that both haloperidol and olanzapine were associated with 
decreased brain weight compared to a control group, suggesting antipsychotic 
medication may affect brain structure (Dorph-Petersen, et al. 2005). Conversely 
pneumoencephalographic studies in the earlier 1900’s, before the advent of 
antipsychotic medication, reported ventricular progression (Moore, et al. 1935). 
Although such early reports were methodologically less rigorous than current MRI 
studies, they suggest that progressive changes are not a result of medication. In 
addition, for studies included in this meta-analysis, the only significant correlations 
of medication compliance and ventricular change suggested medication slows 
ventricular dilation.  
 
Why did early CT studies not detect progressive changes in ventricular volume? 
Early cross-sectional CT studies in schizophrenia did not consistently find a 
correlation between duration of illness and ventricular volume (Weinberger, et al. 
1979), and most CT longitudinal studies could not find a progressive change in 
volume (Nasrallah, et al. 1986; Vita, et al. 1988), a notable exception being the study 
by Davis et al. (Davis, et al. 1998). Based on these earlier studies, it was concluded by 
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some researchers that ventricular volume was static after illness onset. However 
early CT longitudinal studies used less sensitive measures than those available today 
to quantify brain structure, many quantifying ventricular size from only one scan 
slice for analyses. In addition nearly all CT studies included less than 25 patients 
suggesting these studies were underpowered to detect the small change in volume 
over time. From the effect size calculated in this meta-analysis a longitudinal study 
would be required to recruit 63 patients and 63 controls (alpha=0.05, power=0.8) 
and a less powerful cross sectional study would require considerably more subjects. 
Weinberger and McClure (2002) have criticised longitudinal MRI studies, stating that 
there is too much variation between study results, impossibly large changes in brain 
volume, and that other factors could explain the findings such as medication, alcohol 
and substance abuse, and non-stimulating environments. We agree that inter-study 
heterogeneity is high, although this is common in both the neuroimaging and 
psychiatry literature and likely due to different patient populations, imaging 
methodologies and analysis techniques. Performing a random effects meta-analysis 
allows this to be taken into account and provides an estimate of inter-study 
variability. The heterogeneity index of 63% in this meta-analysis is comparable to 
values seen in our previous meta-analysis of cross sectional MRI studies in bipolar 
disorder (Kempton, et al. 2008) which varied from 0% to 91% depending on the brain 
structure analysed. It is true that some longitudinal studies report large changes in 
volume and this may have been caused by scanner and outlining changes between 
the baseline and follow-up scan, however by using effect sizes in the meta-analysis 
this issue is circumvented by taking into account the change in the control group. At 
this stage we cannot discount confounding variables such as alcohol and substance 
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abuse and unstimulating environments, although our analysis of within study 
correlations suggest that medication compliance does not increase ventricular 
progression.  
 
Limitations 
A limitation of this study is that only ventricular volumes have been analysed. In this 
initial meta-analysis we chose the lateral ventricles due to the robust difference 
between patients and controls observed in cross-sectional studies, and because a 
large number of longitudinal studies have measured this region. In the meta-
regression analysis we were limited to analysing variables which were consistently 
reported in the individual studies, thus we were unable to examine measures which 
may influence progressive changes such as specific medications, unstimulating 
environments and co-morbid conditions. Although the case control meta-analysis is 
statistically high powered the meta-regression analysis of clinical variables is low 
powered and may be prone to type II errors. Large, well controlled longitudinal 
studies may be able to examine these variables more effectively.   
 
When does ventricular enlargement start in schizophrenia? 
Six different trajectories in ventricular volume in patients with schizophrenia are 
illustrated (figure 3). Although not exhaustive, the graphs demonstrate popular 
models including variations of the neurodevelopmental and neurodegenerative 
hypotheses. The results of this meta-analysis and other studies can be used to select 
the most likely trajectory. In our meta-analysis we have shown that there are 
progressive changes in ventricular volume in patients with schizophrenia, which 
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would eliminate models a), c) and e). In addition meta-analyses of first episode 
patients with schizophrenia show that there are enlarged ventricles at illness onset 
(Steen, et al. 2006; Vita, et al. 2006), suggesting that model d) is incorrect. Thus we 
speculate that the true trajectory in patients with schizophrenia is either model b) an 
abnormal brain developmental process that begins close to birth with progressive 
changes throughout life, or model f) progressive changes starting in the prodromal 
phase of the illness.  The trajectories may also be modulated by psychotic episodes 
and periods of remission (Garver, et al. 2000), although we were unable to examine 
this in the meta-analysis, as the majority of studies reported data from two time 
points only.  It should be noted that the rate of progression is based on an average 
from the studies included in the meta-analysis, and may not be valid for ages and 
durations of illness outside the ranges reported by studies incorporated in the meta-
analysis. Prospective longitudinal studies of children at genetic high-risk for 
schizophrenia and those beginning at least if not premorbid, in the prodromal stage 
of illness will be required to determine which is the most likely trajectory between b 
and f. Such studies would also reveal whether progressive change occurs even 
before clinical illness begins, what its lifetime course is, and whether the timing of 
changes varies among individuals with the same clinical disease. 
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FIGURE LEGENDS 
Figure 1 Title: Flow chart showing study selection for the meta-analysis 
 
Figure 2 Title: Meta-analysis forest plot of longitudinal changes in ventricular volume 
in patients with schizophrenia compared to controls. 
Figure 2 legend: The effect size is shown for each study with the pooled effect size 
indicated by the gray diamond. Error bars are 95% confidence intervals and the 
effect size is Hedges g which is Cohens’ d with an adjustment for small sample sizes. 
Abbreviations: Olz=Olanzapine, Hal=Haloperidol, FE=First Episode, ME=Multiple 
Episode 
 
Figure 3 Title: Schematic of lateral ventricle volume trajectories over the lifetime in 
patients with schizophrenia compared to control subjects  
Figure 3 legend: Six proposed trajectories are shown. In each graph the horizontal 
axis is age and the vertical axis is lateral ventricular volume in ml. The mean 
trajectory of healthy controls and patients with schizophrenia is indicated by the 
black and red curve respectively. Mean age of onset of schizophrenia is indicated by 
the dashed vertical line. The control curve is for illustrative purposes but is based on 
the 3 studies covering a combined span of birth-80 years (Giedd, et al. 1996; 
Knickmeyer, et al. 2008; Marcus, et al. 2007). The trajectories are divided into non-
progressive and progressive models (left, right) and at what time dilation starts (top, 
middle and bottom). The results of this meta-analysis and meta-analyses of patients 
with first episode schizophrenia argue for trajectory b) or f) (see discussion).    
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Table 1 
 
Study Diagnosis No. 
Patients 
No. 
Controls 
Mean 
interscan 
interval for 
patients 
(years) 
Mean 
patient 
age 
at 
baseline 
scan 
Mean duration 
of illness at 
baseline scan 
(years) 
Degreef et al.  
1991  
RDC schizophrenia 13 8 1.25 25.1 First episode 
DeLisi et al. 
1997 
SADS schizophrenia 
(n=33), schizoaffective 
disorder (n=8), 
psychosis NOS (n=2), 
other (n=6) 
50 20 4.7 27.4 First episode 
Nair et al. 
1997  
DSM-IV schizophrenia 
(n=13) schizoaffective 
(n=4) psychosis NOS 
(n=1) 
18 5 2.58 30.4 8.6 
Rapoport et 
al. 1997  
DSM-III-R 
schizophrenia 
16 24 2.23 14.8 4.6 
Mathalon et 
al. 2001  
DSM-III-R 
schizophrenia 
24 25 3.6 39.4 15.3 
Puri et al. 
2001  
DSM-IV schizophrenia 24 12 0.59 28.5 First episode 
Saijo et al. 
2001  
DSM-III-R 
schizophrenia 
15 12 10 37.5 15.1 
James et al. 
2002  
DSM-III-R 
schizophrenia 
16 16 2.71 16.6 2 
Ho et al. 2003  DSM-IV schizophrenia 73 23 3.3 24.5 3 
Lieberman et 
al. 2005  
DSM-IV schizophrenia, 
schizophreniform, 
schizoaffective disorder 
73 44 1 23.8 1.2 
Whitworth et 
al. 2005  
DSM-III-R 
schizophrenia 
38 20 1 26.5 3.9 
Nakamura et 
al. 2007  
DSM-III-R 
schizophrenia 
17 26 10.45 24.7 First episode 
van Haren et 
al. 2008  
CASH schizophrenia 96 113 1.67 32.2 11 
Mean (SD) - 36.4 (27.8) 26.8 
(27.7) 
3.5 (3.2) 27.0 (7.0) 7.2 (5.5) 
 
Abbreviations: RDC=Research Diagnostic Criteria, SADS=Schedule of Affective 
Disorders and Schizophrenia, CASH= Comprehensive Assessment of Symptoms and 
History 
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Table 2 
 
Study Mean Change in ml (SD) Mean Percentage change (SD) 
 
Patients  Controls  Patients  Controls  
Degreef et al. 1991  -1.05(2.05) -0.08(1.17) -4.47(9.78) -0.24(7.26) 
DeLisi et al. 1997  0.31(0.41) 0.13(0.38) 5.58(6.70) 1.50(7.65) 
Nair et al. 1997  2.18(1.65) 0.76(0.56) 22.1(16.4) 8.80(8.78) 
Rapoport et al. 1997  3.32(3.29) -0.21(0.16) 24.5(29.6) 0.16(16.10) 
Mathalon et al. 2001  1.60(2.47) 0.72(1.32) NA NA 
Puri et al. 2001  0.59(2.03) 0.04(0.55) NA NA 
Saijo et al. 2001  NA NA 22.9(18.7) 5.10(15.00) 
James et al. 2002  0.63(1.54) 0.22(1.02) 4.13(7.36) 2.51(9.89) 
Ho et al. 2003  0.78(2.43) 0.30(1.13) 5.69(15.46) 2.45(9.13) 
Lieberman et al. 2005  Olz group 
0.37(3.56) 
Hal group 
0.37(3.17) 
0.34(1.72) NA NA 
Whitworth et al. 2005  FE group 
0.29(0.57) 
ME group 
0.16(0.38) 
0.14(0.16) NA NA 
Nakamura et al. 2007  NA NA 10.45(7.67) 1.03(3.34) 
van Haren et al. 2008  1.67(2.88) 1.02(1.80) NA NA 
 
 
Abbreviations: Olz=Olanzapine, Hal=Haloperidol, FE=First Episode, ME=Multiple 
Episode, NA=Data not available 
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MEDLINE keyword search
n=219 studies
Longitudinal MRI studies of 
patients with schizophrenia / 
psychosis disorders (n=92)
Longitudinal MRI studies
of lateral ventricles (n=33)
Studies included in 
meta-analysis (n=13)
Excluded reviews, 
cross-sectional 
studies, case 
studies (n=127)
Excluded studies not 
measuring lateral 
ventricles (n=59)
Excluded: 
-overlapping patient 
samples (n=11)
-no means/SD (n=5)
-no control group (n=3)
-other (n=1)
See also table 1
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